Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1512

Sort by

Sort Order Select

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Leukemia secondary to myeloproliferative neoplasms

Andrew J. Dunbar, Raajit K. Rampal, Ross Levine

Blood (2020) 136 (1): 61–70.

https://doi.org/10.1182/blood.2019000943

Published: 2020

Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell

Blood (2019) 134 (Supplement_1): 3801.

https://doi.org/10.1182/blood-2019-128511

Published: 2019

Journal Articles

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

Christoph Kornauth, Charles Herbaux, MD MSc, Bernd Boidol, PhD, Chantal Guillemette, Patrick Caron, Stéphanie Poulain, MD PhD, Olivier Tournilhac, Marius E Mayerhoefer, Ulrich Jaeger, MD, Stefan Kubicek, Matthew S. Davids, MD, Philipp Bernhard Staber, MD PhD

Blood (2019) 134 (Supplement_1): 3965.

https://doi.org/10.1182/blood-2019-124392

Published: 2019

Journal Articles

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Ellen K. Ritchie, MD, Sumaiya K. Miah, BA, Sangmin Lee, MD, Tania Curcio, Pinkal Desai, MDMPH, Jeffrey Ball, MD, Michael B. Samuel, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 3858.

https://doi.org/10.1182/blood-2019-130263

Published: 2019

Journal Articles

Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma

Amin Sobh, PhD, Charlotte Kaestner, Alberto Riva, PhD, Jonathan D. Licht, MD

Blood (2019) 134 (Supplement_1): 3757.

https://doi.org/10.1182/blood-2019-125951

Published: 2019

Journal Articles

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

Blood (2019) 134 (Supplement_1): 3758.

https://doi.org/10.1182/blood-2019-126910

Published: 2019

Journal Articles

Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality

Giulia Petrone, MD MBBS, Shivani Handa, MBBS, Kamesh Gupta, MBBS, Ahmad Khan, MD, Sridevi Rajeeve, MD

Blood (2019) 134 (Supplement_1): 3864.

https://doi.org/10.1182/blood-2019-126177

Published: 2019

Journal Articles

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Joanna S. Yi, MD, Tiffany Chambers, MPH, Kelly D Getz, Tamara P. Miller, MDMSc, Evanette Burrows, MPH, Marla Daves, MD, Philip J. Lupo, PhD MPH, Michael E. Scheurer, PhD MPH, Richard Aplenc, MD PhD, Karen R. Rabin, MD PhD, Maria Monica J. Gramatges, MD PhD

Blood (2019) 134 (Supplement_1): 3814.

https://doi.org/10.1182/blood-2019-123992

Published: 2019

Journal Articles

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Dimitrios Mougiakakos, MD, Simon Voelkl, PhD, Christian Bach, Andrej Stoll, Katrin Bitterer, Fabian Beier, MD, Jan Endell, Rainer Boxhammer, Jörg Thomas Bittenbring, MD, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 4064.

https://doi.org/10.1182/blood-2019-124886

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes

Ipsita Pal, PhD, Yu Ri Kim, MD, Sohani Das Sharma, PhD, Prabhjot S. Mundi, MD, Andre M. Grilo, PhD, Luke E Berchowitz, PhD, Mingzhao Zhu, PhD, Hull G. Kenneth, PhD, Daniel Romo, PhD, Owen O'Connor, MD PhD, Marko Jovanovic, PhD, Changchun Deng, MD PhD

Blood (2019) 134 (Supplement_1): 4067.

https://doi.org/10.1182/blood-2019-131816

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Oliver Tomkins, BMBS, MRCP, Joshua Bomsztyk, Helen McCarthy, MBBS, PhD, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, MBBS, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 4016.

https://doi.org/10.1182/blood-2019-129212

Published: 2019

Journal Articles

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Lauren K. Meyer, Katherine Verbist, PhD, Sabrin Albeituni, PhD, Rachel Bassett, Michelle L. Hermiston, MD PhD, Kim E. Nichols, MD

Blood (2019) 134 (Supplement_1): 81.

https://doi.org/10.1182/blood-2019-129112

Published: 2019

Journal Articles

DNA Polymerases Pol θ/Pol η Involved in Error-Prone DNA Repair Are Highly Expressed in Multiple Myeloma and Upregulated By DNA Damage

Blood (2019) 134 (Supplement_1): 4364.

https://doi.org/10.1182/blood-2019-125163

Published: 2019

Journal Articles

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Stephen Reeder, BSc, Clare Coveney, PhD, Sergio Rutella, MDPhDFRCPath

Blood (2019) 134 (Supplement_1): 2726.

https://doi.org/10.1182/blood-2019-124717

Published: 2019

Journal Articles

Impact of Upfront Chemotherapy on Overall Survival in Isolated Myeloid Sarcoma

Konstantinos Lontos, MD, Jonathan G. Yabes, PhD, Michael Boyiadzis, MD

Blood (2019) 134 (Supplement_1): 2608.

https://doi.org/10.1182/blood-2019-123308

Published: 2019

Journal Articles

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Erin Lynn Crowgey, PhD, Todd E Druley, MD PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 2683.

https://doi.org/10.1182/blood-2019-131050

Published: 2019

Journal Articles

Genome-Scale CRISPR-Cas9 Synthetic Lethal Screening of AML Cell Line Identified Functional Modulators of Etoposide Resistance Predictive of Clinical Outcome in AML Patients

Roya Rafiee, M.Sc., PhD, Amin Sobh, PhD, Abdelrahman H. Elsayed, MSc, Abderrahmane Tagmount, PhD, Chris D Vulpe, MD PhD, Jatinder K Lamba, M.Sc., PhD

Blood (2019) 134 (Supplement_1): 2685.

https://doi.org/10.1182/blood-2019-131312

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

DARTs point the way forward in AML

Leukemia secondary to myeloproliferative neoplasms

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Identification of Genetic Vulnerabilities and Synthetic-Lethal Targets in NSD2-High Multiple Myeloma

A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL

Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

DNA Polymerases Pol θ/Pol η Involved in Error-Prone DNA Repair Are Highly Expressed in Multiple Myeloma and Upregulated By DNA Damage

Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia

Impact of Upfront Chemotherapy on Overall Survival in Isolated Myeloid Sarcoma

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Genome-Scale CRISPR-Cas9 Synthetic Lethal Screening of AML Cell Line Identified Functional Modulators of Etoposide Resistance Predictive of Clinical Outcome in AML Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only